<DOC>
	<DOCNO>NCT00790218</DOCNO>
	<brief_summary>This trial test safety efficacy CF102 patient advance liver cancer . Successive group patient give high dos CF102 mouth twice-daily basis . Treatment assess adverse effect effect tumor .</brief_summary>
	<brief_title>A Phase 1-2 Study CF102 Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description>This multicenter , open-label , non-randomized , dose-escalation study , conduct 2 phase : dose-escalation phase , determine MTD CF102 evaluate safety/tolerability , PK , pharmacodynamic , preliminary clinical activity ; dose-confirmation phase , cohort expansion MTD ( ie , RP2D ) CF102 . Subjects treat oral dos CF102 consecutive , 28-day cycle . The initial dose CF102 1 mg twice daily ( BID ) , subsequent escalation 5 25 mg BID , unless limited toxicity . Subjects evaluate weekly first cycle , every 2 week Cycles 2 3 , end subsequent cycle , 6 cycle CF102 treatment . Subjects return follow-up visit 28 day completion last dose study drug .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>1 . Diagnosis HCC : For patient without underlying cirrhosis , diagnosis HCC document cytology and/or histology For patient underlie cirrhosis , diagnosis HCC establish accord American Association Study Liver Diseases Practice Guideline algorithm ( Appendix V ) . 2 . HCC advance , refractory , metastatic , standard therapy expect curative . 3 . At least 18 year age . 4 . For subject doseconfirmation ( RP2D ) phase : Measurable disease , use Response Evaluation Criteria Solid Tumors ( RECIST , Appendix IV ) . ( Note lesion subject radiotherapy chemoembolization use target lesion . ) 5 . Eastern Collaborative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 , 2 baseline . 6 . The following laboratory value must document within 3 day prior initiation study drug : Absolute neutrophil count ( ANC ) great equal 1 x 109/L Platelet count great equal 50 x 109/L Serum creatinine less equal 2.0 mg/dL Aspartic aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 5 × upper limit normal . Total bilirubin ≤ 3.0 mg/dL . Serum albumin ≥ 3.0 g/dL . International normalized ratio ( INR ) ≤ 2.3 . 7 . Esophageal bleeding varix , present , sclerosed band , bleed episode occur prior 6 month . 8 . Life expectancy ≥ 12 week . 9 . For woman childbearing potential , negative serum pregnancy test result . 10 . Absence active malignancy HCC within 2 year entry , exception basal cell carcinoma squamous cell carcinoma skin . 11 . Provide write informed consent participate . 12 . Willing comply schedule visit , treatment plan , laboratory assessment , study related procedure . 1 . Any chemotherapy , immunomodulatory drug therapy , immunosuppressive therapy , corticosteroid &gt; 20 mg/day prednisone equivalent , growth factor treatment ( e.g. , erythropoietin ) within 14 day prior initiation study drug . 2 . Major surgery radiation therapy within 28 day prior initiation study drug . 3 . Severe liver dysfunction ( ChildPugh Class C hepatic encephalopathy ) . 4 . Active infection require systemic therapy . 5 . Uncontrolled congestive heart failure ( New York Heart Association Classification 3 4 ) , angina , myocardial infarction , cerebrovascular accident , coronary/peripheral artery bypass graft surgery , transient ischemic attack , pulmonary embolism within 3 month prior initiation study drug . 6 . History ongoing cardiac dysrhythmias require treatment , atrial fibrillation grade , persistent prolongation QTc ( Fridericia ) interval &gt; 450 msec male &gt; 470 msec female . 7 . Pregnant lactate female . 8 . Women childbearing potential , unless agree use dual contraceptive method , opinion Principal Investigator ( PI ) , effective adequate patient 's circumstance study drug . 9 . Men partner woman childbearing potential , unless agree use effective , dual contraceptive method ( i.e. , condom , female partner use oral , injectable , barrier method ) study drug . 10 . Known human immunodeficiency virus acquire immunodeficiency syndromerelated illness . 11 . Any severe , acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere informed consent process and/or compliance requirement study , may interfere interpretation study result , investigator 's opinion , would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>Hepatoma</keyword>
	<keyword>HCC</keyword>
</DOC>